Literature DB >> 967774

Safeguards in the treatment of schizophrenia with propranolol.

N J Yorkston, S A Zaki, J F Themen, C W Havard.   

Abstract

Early results for an uncontrolled study of 555 patients with florid schizophrenia suggest that propranolol can be used safely in high dosage, and in a proportion of cases it appears to control schizophrenic symptoms. This method of treatment is now being submitted to controlled trial. Evdence from this uncontrolled study suggests that there was a therapeutic dose range in which symptoms steadily improved as a low dose was ineffective and a high dose, particularly if reached too rapidly, caused toxic effects. Rapid increases (400-800 mg) in the daily total intake when given in divided doses (4 to 10/day) produced gross toxic effects that included ataxia with unprotected falls, drop attacks, visual hallucinations, and confusional states. Severe toxic effects were uncommon when the dose was raised by regular, gradual increments (e.g. by 40-80 mg/day), when propranolol was given twice daily, when the dose was held steady as the patient started to improve, and when the daily total dose was reduced if the fall in pulse rate or blood pressure was excessive, or if there was evidence of toxicity. The observation of gradual, progressive improvement was the most valuable positive guide to the dose of propranolol. All schizophrenic symptoms remitted, at least temporarily, in 26 of 55 patients (in 15 of 17 patients who had been ill for less than one year and in 11 of 38 patients who had been ill for longer than a year). Patients who then stopped propranolol usually relapsed within hours or days.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 967774

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  5 in total

1.  Antipsychotic effect of propranolol on chronic schizophrenics: study of a gradual treatment regimen.

Authors:  A Elizur; Z Segal; A Yeret; S Davidson; A Atsmon
Journal:  Psychopharmacology (Berl)       Date:  1979-01-31       Impact factor: 4.530

2.  Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment.

Authors:  D H Staniforth; N J Yorkston; S A Zaki
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  Beta-blockers and psychometric performance: studies in normal volunteers.

Authors:  D G McDevitt
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  The effect of propranolol on CSF amine metabolites in psychiatric patients.

Authors:  D J King; S J Cooper; J Liddle
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

5.  Efficacy of propranolol on schizophrenic thought disorder.

Authors:  B B Sethi; S Dube
Journal:  Indian J Psychiatry       Date:  1981-10       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.